158984-84-0

Basic information

• Product Name: tert-butyl 6-(trifluoroMethylsulfonyloxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate
• Synonyms: tert-butyl 6-(trifluoroMethylsulfonyloxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate;tert-butyl 6-(trifluoroMethylsulfonyloxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate-11
• CAS NO: 158984-84-0
• Molecular Formula: C₁₅H₁₈F₃NO₅S
• Molecular Weight: 381.3673296
• Mol File: 158984-84-0.mol

Chemical Properties

• Melting Point: 48-51 °C
• Boiling Point: 430.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.382±0.06 g/cm3(Predicted)
• PKA: -1?+-.0.20(Predicted)
• CAS DataBase Reference: tert-butyl 6-(trifluoroMethylsulfonyloxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 6-(trifluoroMethylsulfonyloxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate(158984-84-0)
• EPA Substance Registry System: tert-butyl 6-(trifluoroMethylsulfonyloxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate(158984-84-0)

Safety Data

• Hazardous Substances Data: 158984-84-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 6-(trifluoroMethylsulfonyloxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate is used as a chemical intermediate for the synthesis of pharmaceutical compounds. Its unique structure, including the trifluoromethylsulfonyloxy group as a leaving group and the dihydroisoquinoline-2(1H)-carboxylate group as a fused bicyclic heterocyclic compound, makes it a valuable building block for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, tert-butyl 6-(trifluoroMethylsulfonyloxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate is utilized as a versatile reagent for the preparation of a variety of organic compounds. Its functional groups can participate in numerous chemical reactions, enabling the formation of diverse molecular structures with potential applications in various industries.
Used in Chemical Reactions:
Tert-butyl 6-(trifluoroMethylsulfonyloxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate is used as a reactant in various chemical reactions, taking advantage of its tert-butyl group for steric hindrance and the trifluoromethylsulfonyloxy group as a leaving group. This allows for the formation of new chemical bonds and the creation of novel compounds with specific properties and uses.

Upstream product

• 358-23-6 trifluoromethylsulfonic anhydride 
• 158984-83-9 N-tert-butoxycarbonyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 59839-23-5 6-hydroxy-1,2,3,4-tetrahydroisoquinoline hydrobromide 
• 14446-24-3 6-hydroxy-1,2,3,4-tetrahydroisoquinoline 
• 42923-77-3 6-methoxy-1,2,3,4-tetrahydro-isoquinoline 
• 22246-12-4 6-methoxy-1,2,3,4-tetrahydro-1-oxoisoquinoline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 63905-73-7 6-hydroxy-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 

Downstream Products

• 170097-66-2 3,4-Dihydro-1H-isoquinoline-2.6-dicarboxylic acid 2-tert-butyl ester-6-methyl ester 
• 949922-27-4 1-(1,2,3,4-tetrahydroisoquinolin-6-yl)ethanone 
• 1007579-62-5 3-(1,2,3,4-tetrahydro-6-isoquinolinyl)benzamide 
• 1007579-56-7 1,1-dimethylethyl 6-[3-(aminocarbonyl)phenyl]-3,4-dihydro-2(1H)-isoquinolinecarboxylate 
• 166398-33-0 tert-butyl 6-cyano-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 893566-72-8 6-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 189745-26-4 tert.-butyl 6-(3,5-dichlorophenyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate 
• 189745-24-2 6-(4-chlorophenyl)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 170097-67-3 2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 

Relevant articles and documents

Electrochemical Approach for Direct C-H Phosphonylation of Unprotected Secondary Amine

Direct α-phosphonylation of an unprotected secondary amine in a single step is of practical importance to amino phophophates. However, this protocol is limited due to the high redox barrier of unprotected amine. In this paper, we report C-H phosphonylation of an unprotected secondary amine via an electrochemical approach in the presence of catalytic carboxylate salt. This metal-free and exogenous oxidant-free method furnishes diverse target molecules with satisfactory yield under mild reaction conditions. Successful application of the protocol in a gram-scale experiment demonstrates the potential utility for further functionalization.

SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS

The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related di

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

T-type calcium channel inhibitor

The present invention addresses the problem of providing novel compounds that have T-type voltage-gated calcium channel-blocking activity and are useful particularly in treating pain, chronic kidney disease, and atrial fibrillation. Provided are novel tri

T-TYPE CALCIUM CHANNEL BLOCKER

It is an object to provid a novel compound that has an excellent T-type calcium channel inhibitory activity and is specifically useful for prevention or treatment of pain, chronic kidney disease and atrial fibrillation. The present invention provides a no

1-(2-hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulators

We present a novel series of selective androgen receptor modulators (SARMs) which shows excellent biological activity and physical properties. 1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)-indoline-4-carbonitriles showed potent binding to the androgen receptor (AR) and activated AR-mediated transcription in vitro. Representative compounds demonstrated diminished activity in promoting the intramolecular interaction between the AR carboxyl (C) and amino (N) termini. This N/C-termini interaction is a biomarker assay for the undesired androgenic responses in vivo. In orchidectomized rats, daily administration of a lead compound from this series showed anabolic activity by increasing levator ani muscle weight. Importantly, minimal androgenic effects (increased tissue weights) were observed in the prostate and seminal vesicles, along with minimal repression of circulating luteinizing hormone (LH) levels and no change in the lipid and triglyceride levels. This lead compound completed a two week rat toxicology study, and was well tolerated at doses up to 100 mg/kg/day, the highest dose tested, for 14 consecutive days.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

A method of treatment using pharmaceutical compositions containing novel antagonists or inverse agonists at opioid receptors for the treatment of binge eating disorder, anorexia nervosa, bulimia nervosa, excess drug or alcohol use, or eating disorder not otherwise specified.

Expeditious one-pot, four-step preparation of 2-t-butoxycarbonyl-6-hydroxy- 1,2,3,4-tetrahydroisoquinoline and an improved conversion to its 6-cyano derivative

3-Methoxy-phenethylamine was subjected to a sequential imination/Pictet- Spengler/demethylation/Boc protection sequence that allowed a one-pot preparation of N-Boc-6-hydroxy-1,2,3,4-tetrahydroisoquinoline 1. This intermediate was elaborated almost quantit

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.